The G2 Diagnostic Stock Index gained about 14 percent for the second half of the year (July 26 to Dec. 27) and was up nearly 50 percent for the full year 2013 (Jan. 2 to Dec. 27). Thirteen stocks gained for the period, while two stocks lost ground. The G2 Diagnostic Stock Index outperformed the broader stock markets for the year even though the Nasdaq and Standard & Poor’s (S&P) both gained widely over the period. The Nasdaq was up 34 percent during 2013, while the S&P increased 26 percent. The G2 Diagnostic Stock Index’s outperformance of the S&P was carried by half of the stocks, with eight companies individually outperforming the S&P. Five stocks had gains for the year but did not perform as well as the S&P. Three of the diagnostic stocks with the largest gains had gains nearing or in excess of 100 percent. Microarray maker Affymetrix (Santa Clara, Calif.) gained 164 percent in 2013, followed by Illumina (San Diego) at 99 percent and Alere (Waltham, Mass.) at 89 percent. Affymetrix’s gains were in part driven by positive results from the company’s corporate restructuring program. Additionally, this fall the company released the Minimal Signature E. coli Array, […]